Armando Magrelli

List of Publications by Citations

28 papers	1,275 citations	13 h-index	29 g-index
29 ext. papers	1,393 ext. citations	8.2 avg, IF	3.3 L-index

#	Paper	IF	Citations
28	Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. *Blood*, **2007**, 109, 4944-51	2.2	422
27	White collar-1, a central regulator of blue light responses in Neurospora, is a zinc finger protein.. *EMBO Journal*, **1996**, 15, 1650-1657	13	350
26	Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson¶s disease-associated GPR37/parkin-associated endothelin-like receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10189-94	11.5	63
25	Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. *Cancer Research*, **2009**, 69, 8438-46	10.1	62
24	Altered microRNA Expression Patterns in Hepatoblastoma Patients. *Translational Oncology*, **2009**, 2, 157-63	4.9	59
23	Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. *Experimental Dermatology*, **2011**, 20, 932-7	4	50
22	In utero exposure to di-(2-ethylhexyl) phthalate affects liver morphology and metabolism in post-natal CD-1 mice. *Reproductive Toxicology*, **2010**, 29, 427-32	3.4	40
21	Splicing of the rolA transcript of Agrobacterium rhizogenes in Arabidopsis. *Science*, **1994**, 266, 1986-8	33.3	33
20	MicroRNA profiling of multiple osteochondromas: identification of disease-specific and normal cartilage signatures. *Clinical Genetics*, **2010**, 78, 507-16	4	29
19	Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease. *British Journal of Dermatology*, **2010**, 162, 518-26	4	28
18	The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. *Human Molecular Genetics*, **2010**, 19, 752-60	5.6	28
17	European regulatorsTviews on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. *Neuromuscular Disorders*, **2019**, 29, 514-516	2.9	27
16	Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. *Journal of Cellular Physiology*, **2016**, 231, 224-32	7	19
15	The role of microRNAs in the biology of rare diseases. *International Journal of Molecular Sciences*, **2011**, 12, 6733-42	6.3	11
14	Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions. *Drug Discovery Today*, **2018**, 23, 26-48	8.8	10
13	Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in Europe. *Drug Discovery Today*, **2018**, 23, 90-100	8.8	10
12	Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy. *Orphanet Journal of Rare Diseases*, **2019**, 14, 154	4.2	8

List of Publications

11	Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective. *British Journal of Clinical Pharmacology*, **2021**, 87, 4183-4196	3.8	7
10	Genomic Analysis of GPR37 and Related Orphan G-Protein Coupled Receptor Genes Highly Expressed in the Mammalian Brain. *Current Genomics*, **2001**, 2, 253-260	2.6	5
9	Defining orphan conditions in the context of the European orphan regulation: challenges and evolution. *Nature Reviews Drug Discovery*, **2019**, 18, 479-480	64.1	5
8	Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases. *Drug Discovery Today*, **2020**, 25, 274-291	8.8	4
7	Predictive medicine and biomarkers: the case of rare diseases. *Personalized Medicine*, **2012**, 9, 143-146	2.2	2
6	Reply to the article "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy". *Epilepsy and Behavior*, **2020**, 107, 106866	3.2	1
5	The Italian National Centre for Rare Diseases: where research and public health translate into action. *Blood Transfusion*, **2014**, 12 Suppl 3, s591-605	3.6	1
4	Regulatory Standards in Orphan Medicinal Product Designation in the EU. *Frontiers in Medicine*, **2021**, 8, 698534	4.9	1
3	Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's Perspective. *Frontiers in Medicine*, **2021**, 8, 744625	4.9	0
2	Reply to the reply of the authors of the review article entitled "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy". *Epilepsy and Behavior*, **2020**, 110, 107168	3.2	
1	Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation.. *Frontiers in Oncology*, **2021**, 11, 809035	5.3	